Combination of GLP-1s and progestin could be linked to lower endometrial cancer risk

Embargoed until: Publicly released: 2026-02-11 03:00

International

Photo by Haberdoedas on Unsplash

GLP-1RA drugs, commonly known as diabetes and weight loss drugs, could be linked to decreased endometrial cancer risk in people with benign uterine diseases when combined with progestin, according to international researchers. The team looked at data from 444,820 women who had some kind of uterine issue, such as abnormal bleeding, an endometrial polyp, and more. When comparing the effect of usual management – progestin – to a combination therapy of progestin and GLP-1RAs, the team found the combination therapy was associated with a lower risk of endometrial cancer.

News release

From: JAMA

GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases

About The Study: In this cohort study of women with benign uterine pathology or endometrial hyperplasia, combined glucagon-like peptide-1 receptor agonist (GLP-1RA) and progestin was associated with reduced endometrial cancer risk. Further investigation is warranted to assess its applicability and underlying mechanisms.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo lifts.

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Johns Hopkins University, USA

Funder: None reported.

Media Contact/s

Contact details are only visible to registered journalists.